- For Print
- March 22, 2022
Eisai Co., Ltd.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu; hereafter, “Sysmex”) and Eisai Co., Ltd. (Headquarters: Tokyo; CEO: Haruo Naito; hereafter, “Eisai”) are aiming to leverage their individual technologies and expertise in the creation of next-generation diagnostic agents that may aid in early diagnosis of dementia, treatment selection, and regular confirmation of treatment efficacy. Sysmex and Eisai have a non-exclusive comprehensive agreement for the creation of novel diagnostic agents for the dementia area.
Sysmex and Eisai announced today that an oral presentation on the use of the HISCL™ Automated Immunoassay System in the clinical evaluation of the plasma Aβ1-42/Aβ1-40 ratio was delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD™ 2022) held in Barcelona, Spain from March 15 to 20 2022.
Fully Automated Plasma Beta-Amyloid Immunoassays Predict Amyloid Pathology Defined by Amyloid PET
Kazuto Yamashita1, Masao Miura1, Shunsuke Watanabe1, Kengo Ishiki1, Yuji Arimatsu2, Yasuhiro Irino1, Toshiko Kubo3, Kei Hagino2, Kota Nagai4, David Verbel5, Akihiko Koyama6, Shobha Dhadda7, Hayato Niiro8, Shigeki Iwanaga1, Toshiyuki Sato1, Tomokazu Yoshida9, Atsushi Iwata101Central Research Laboratories, Sysmex Corporation, Kobe, Japan; 2Business Incubation Division, Sysmex Corporation, Kobe, Japan; 3Sysmex R&D Center Americas, Mundelein, Illinois, USA; 4Japan and Asia Clinical Development Department, Eisai Co., Ltd., Japan; 5Biostatistics, Eisai Inc., Woodcliff Lake, NJ, USA; 6Translational Science, Eisai Inc., Woodcliff Lake, NJ, USA; 7Biostatistics and Project Operations, Eisai Inc., Woodcliff Lake, NJ, USA; 8Medical Affairs Division, Sysmex Corporation, Kobe, Japan; 9Sysmex Corporation, Kobe, Japan; 10Department of Neurology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
|Type of presentation||Virtual, On-Demand Oral|
|Overview of presentation||
Accumulation of β-amyloid peptide (Aβ) (amyloid pathology) in the brain is a hallmark of Alzheimer’s disease (AD). Several clinical trials on disease-modifying therapies (DMTs) targeting Aβ have been conducted. The US Food and Drug Administration has recently granted accelerated approval for an anti-amyloid antibody for early AD. Given this background, there is an increasing need for simple, cost-effective diagnostic methods of detecting amyloid pathology in the brain.
Our group previously reported that amyloid PET status was correlated with Aβ1-42/ Aβ1-40 ratio in plasma (hereafter, “plasma Aβ ratio”) and that amyloid pathology in the brain could potentially be predicted using blood biomarkers.*1 Our research has focused on the plasma Aβ ratio using clinical specimens. In this presentation, we conducted a clinical evaluation of the plasma Aβ ratio measured using the HISCL Automated Immunoassay System (Sysmex) in comparison with amyloid PET status determined by the Centiloid method*2 in 180 patients (Discovery Study) and 191 patients (Validation Study) clinically diagnosed with mild AD or mild cognitive impairment.
Since measurement of plasma Aβ1-42 and Aβ1-40 in the HISCL is fully automated immunoassay that is less invasive and more accessible, it may contribute to the diagnosis of AD in routine clinical practice. We believe that the plasma Aβ can contribute to early diagnosis, of AD, treatment selection and monitoring of treatment effect.
*1 The 18th R&D Meeting (2021, Sysmex)
*2 Klunk WE et al, Alzheimer’s Dementia (2014)
*3 Shows significant correlation between data from 2 quantitative data distributions. In the present analysis, we calculated Spearman’s rank correlation coefficients, which indicate correlations between rank data.
*4 Schindler SE et al, Neurology, 93, e1647-e1659 (2019)
Contacts for inquiries
IR & Corporate Communication
Public Relations Department
Eisai Co., Ltd.
Eisai Inc. (US)